Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study
R. J. Liesner; M. Abashidze; O. Aleinikova; C. Altisent; M. J. Belletrutti; A. Borel‐Derlon; M. Carcao; H. Chambost; A. K. C. Chan; L. Dubey; J. Ducore; N. A. Fouzia; M. Gattens; Y. Gruel; B. Guillet; N. Kavardakova; M. El Khorassani; A. Klukowska; T. Lambert; S. Lohade; M. Sigaud; V. Turea; J. K. M. Wu; V. Vdovin; A. Pavlova; M. Jansen; L. Belyanskaya; O. Walter; S. Knaub; E. J. Neufeld
Author Information: Great Ormond Hospital for Children NHS Trust Haemophilia Centre
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.